02-23-04

EXPRESS MAIL CERTIFICATE

"Express Mail" Label No.	:	EV 127 541 682 US
Serial No.	:	10/660,131
Applicant(s)	:	Munn, David H.
Filing Date	:	September 11, 2003
Title:	:	Chemokine Receptor Antagonists as Therapeutic Agents
Examiner	:	Unassigned
Group Art Unit	:	Unassigned
Type of Document(s)	:	Express Mail Certificate (No. EV 127 541 682 US); Transmittal Form PTO/SB/21; Supplemental Information Disclosure Statement (in dup.); References (106 Copies) ; Supplemental IDS Form PTO/SB/08A; and Return Postcard

I hereby certify that the documents identified above are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and are addressed to the Assistant Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

Kay Farmer (signature)
Kay Farmer

Date of Deposit: February 18, 2004

Please type a plus sign (+) inside this box → [+]

EV 127 541 682 US PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	Munn, David H.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351/287806

Total Number of Items in This Submission (including Transmittal Form) [ ]

ENCLOSURES *(check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment / Response
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☒ Information Disclosure Statement (in duplicate)
- ☐ Certified Copy of Priority Document(s)
- ☐ Response to Missing Parts/ Incomplete Application
  - ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Assignment Papers *(for an Application)*
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- ☐ Proprietary Information
- ☐ Status Letter
- ☒ Other Enclosure(s) *(please identify below):*
  Express Mail Certificate – EV 127 541 682 US
  PTO/SB/08A
  References: 106
  Return Postcard

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Cynthia B. Rothschild, Esq. Reg. No. 47,040
Signature	
Date	February 18, 2004

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United Stats Postal Service s first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: [ ]

Typed or printed name	SENT VIA EXPRESS MAIL		
Signature		Date	

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of	:	David H. Munn
Serial No.	:	10/660,131
Filed	:	September 11, 2003
For	:	CHEMOKINE RECEPTOR ANTAGONISTS AS THERAPEUTIC AGENT
Examiner	:	Unassigned
Group Art Unit	:	Unassigned

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants submit herewith on Form PTO/SB/08A a listing of one-hundred six (106) documents known to the Applicants and/or their attorney. Applicants respectfully request consideration of the cited documents and making the same of record in the prosecution of the above-identified application. In so doing, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the present application, or to establish that such references are not prior art. Copies of the documents are enclosed, numbered and labeled for identification purposes except for item 66 which is a book.

This statement should not be construed as a representation that more material information does not exist or that a search of the relevant art has been made. It is respectfully requested that the references listed on the attached form PTO/SB/08A be expressly considered by the Examiner, made of record in the application, and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being submitted prior to the mailing of a first substantive Office Action in this application, and, therefore, no certification or fee is required (37 C.F.R. § 1.97b(3)). However, should any fees be due, the Commissioner is authorized to charge such fees to Deposit Account No. 16-1435. A duplicate of this sheet is attached for that purpose.

Respectfully submitted,

Date: 2-19-04

Cynthia B. Rothschild, Re. No. 47040

KILPATRICK STOCKTON LLP
1001 West Fourth Street
Winston-Salem, North Carolina 27101-2400
(336) 747-7541 Phone
(336) 607-7500 Facsimile
Attorney Docket No.: M0351-287806

M0351-287806
WINLIB01:1032834.1

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	U.S. Patent Document Number	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	5,582,831		Shinitzky, Meir	12/10/96	
	2	5,648,219		MacKay, V.L. et al.	07/15/97	
	3	5,849,589		Tedder, T.F. et al.	12/15/98	
	4	5,851,756		Steinman, R.M. et al.	12/22/98	
	5	5,871,728		Thomson, A.W. et al	02/15/99	
	6	5,994,126		Steinman, R.M. et al.	11/30/99	
	7	6,008,004		Olweus, Johanna et al	12/28/99	
	8	6,080,409		Laus, R. et al.	06/27/00	
	9	6,194,204		Crawford, K.D. et al.	02/27/01	
	10	6,210,662		Laus, R. et al.	04/03/01	
	11	6,224,859		Thomson, A.W. et al.	05-01-01	
	12	6,228,640		Cezayirli, C. et al.	05/08/01	
	13	6,274,378		Steinman, R.M. et al	08/14/01	
	14	6,290,972	B1	Armitage, R.J. et al.	09/18/01	
	15	6,395,876		Munn, D. et al.	05-28-02	
	16	6,451,840	B1	Munn, D. et al.	09-17-02	
	17	2001/0001040 A1		Munn, D. et al.	05-10-01	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Office[3]	Number[4]	Kind Code[2] (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.

[1] Unique citation designation number. [2] See attached Kinds of U.S. Patent Documents. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
	18	ALBERT, M. L., Dendritic cell maturation is required for the cross-tolerization of $CD8^+$ T cells, *Nature Immunol.*, **2**, 1010-1017, 2001	
	19	ALEXANDER, A. M. et al., Indoleamine 2,3-Dioxygenase expression in transplanted NOD islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes, *Diabetes,* **51**:356-364, 2002	
	20	BANCHEREAU, J. et al., Immune and clinical responses in patients with metastatic melanoma to $CD34^+$ progenitor-derived dendritic cell vaccine, *Cancer Res.*, **61**, 6451-6458, 2001	
	21	BANKENSTEIN, T. et al, Cross-priming versus cross-tolerance: are two signals enough?, *Trends in Immunol.*,**23**,171-173, 2002	
	22	BAX, A. et al., MLEV-17-based two-dimensional homonuclear magnetization transfer spectroscopy, *J. Magn. Reson.*, **65**: 355-360, 1985	
	23	BELL, D. et al., In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas, *J. Exp. Med.*, **190**, 1417-1426, 1999	
	24	BENNETT, S. R. et al., Help for cytotoxic-T-cell responses is mediated by CD40 signalling, *Nature,* **393**, 478-480, 1998	
	25	BODENHAUSEN, G. et al., Natural abundance Nitrogen-15 NMR by enhanced heteronuclear spectroscopy, Natural *Chem. Phys. Lett.,* **69:** 185-189, 1980	
	26	CADY, S. G. et al., 1-Methyl-DL-tryptophan, β-(3-Benzofuranyl)-DL-alanine (the Oxygen Analog of Tryptophan), and β-[3-Benzo(b)thienyl]-DL-alanine (the Sulfur Analog of Tryptophan) are competitive inhibitors of Indoleamine 2,3-Dioxygenase, *Arch. Biochem. Biophys.*, **291**, 326-333, 1991	
	27	CELLA, M. et al., Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity:T-T help via APC activation, *J. Exp. Med.,* **184**, 747-752, 1996	
	28	CELLA, M. et al., Plasmacytoid monocytes migrate to inflamed	

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		lymph nodes and produce large amounts of type I interferon, *Nature Medicine,* **5**, 919-923, 1999	
	29	CHEN, S., et al, In vivo inhibition of CC and CX3C Chemokine-induced Leukocyte infiltration and attenuation of glomerulonephritis in Wistar-Kyoto (WKY) rats by vMIP-II, *J. Exp. Med.,* **188:** 193-198 (1998)	
	30	CHEN, W. et al., TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu, *Immunity,* **22**:14**,** 715-725, 2001	
	31	COBBOLD, S. et al., Infectious tolerance, *Curr. Opin. Immunol.,* **10**, 518-524, 1998	
	32	CORNILESCU, G. et al., Protein backbone angle restraints from searching a database for chemical shift and sequence homology, *J. Biomol. NMR,* **13:** 289-302, 1999	
	33	CURIEL, T. J. et al., Tumor immunotherapy: inching toward the finish line, *J. Clin. Invest.,* **109**, 311-312, 2002	
	34	DHODAPKAR, M. V. et al., Mature dendritic cells boost functionally superior $CD8^+$ T-cell in humans without foreign helper epitopes, *J. Clin. Invest.,* **105**, R9-R14, 2000	
	35	DHODAPKAR, M. V. et al., Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells, *J. Exp. Med.,* **193**, 233-238, 2001	
	36	DOAN, T. et al., Peripheral tolerance to human papillomavirus E7 oncoprotein occurs by cross-tolerization, is largely Th-2-independent, and is broken by dendritic cell immunization, *Cancer Res.,* **60**, 2810-2815, 2000	
	37	DONG et al., B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion, *Nature Med.,* **5**, 1365-1369, 1999	
	38	DZIONEK, A. et al., BDCA-2, BDCA-3, and BDCA-4: Three markers for distinct subsets of dendritic cells in human peripheral blood, *J. Immunol.,* **165**, 6037-6046, 2000	
	39	FACCHETTI, F. et al., Plasmacytoid monocytes (so-called plasmacytoid T cells) in Hodgkin's disease, *J. Pathol.,* **158**, 57-65, 1989	
	40	FALLARINO, F. et al., Functional expression of indoleamine 2,3-dioxygenase by murine $CD8\alpha^+$ dendritic cells, *Internat Immunol.,* **14(1)**,65-68, 2002	
	41	FIOCCHI, C., TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for	

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet | 4 | of | 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		chronic inflammation, *J. Clin. Invest.*, **108**, 523-526, 2001	
	42	GALLUCCI, S. et al., Natural adjuvants: Endogenous activators of dendritic cells, *Nat. Med.*, **5**, 1249-1255, 1999	
	43	GORCZYNSKI, R. et al., Dendritic cells expressing TGFβ/IL-10, and CHO cells with OX-2, increase graft survival, *Transplantation Proceedings*, **33**, 1565-1566, 2001	
	44	GROHMANN, U. et al., IL-6 inhibits the tolerogenic function of $CD8\alpha^+$ dendritic cells expressing indoleamine 2,3-dioxygenase, *J. Immunol.*, **167**, 708-714, 2001	
	45	GROUARD, G. et al., The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand, *J. Exp. Med.*, **185**, 1101-1111, 1997	
	46	HEISER, A. et al., Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors, *J. Clin. Invest.*, **109**, 409-417, 2002	
	47	HONEY, K. et al., Dominant regulation: a common mechanism of monoclonal antibody induced tolerance?, *Immunol. Res.*, **20**, 1-14, 1999	
	48	HORUZSKO, A. et al., Maturation of antigen presenting cells is compromised in HLA-G transgenic mice, *Internat Immunol.*, **13**,385-394, 2001	
	49	HWU, P. et al., Indoleamine 2,3-Dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation, *J. Immunol.*, **164**:3596-3599, 2000	
	50	IWASAKI, A. et al., Localization of distinct peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine, *J. Exp. Med.*, **191**, 1381-1393, 2000	
	51	JONULEIT, H. et al., Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions, *Eur. J. Immunol.*, **27**, 3135-3142, 1997	
	52	JONULEIT, H. et al., Dendritic cells as a tool to induce anergic and regulatory T cells, *Trends Immunol.*, **22**, 394-400, 2001	
	53	KIKUCHI, T. et al., Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors, *Blood*, **96**, 91-99, 2000	
	54	KOURILSKY, P. et al., Cytokine fields and the polarization of	

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		the immune response, *Trends in Immunol.*, **22**, 502-509, 2001	
	55	KUDO, Y. et al., Human placental indoleamine 2,3-dioxygenase: cellular location and characterization of an enzyme preventing fetal rejection, *Biochem, Biophys. Acta,* **1500**, 119-124, 2000	
7*	56	LEE et al., Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division, *Immunol.,* **107**: 452-460 (2002)	
	57	LIU, Y. J., Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity, *Cell,* **106**, 259-262, 2001	
	58	MALOY, K. G. et al., Regulatory T cells in the control of immune pathology, *Nature Immunol.,* **2**, 816-822, 2001	
	59	MELLOR, A.L. et al., Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy, *Nat. Immunol.* **2**: 64-68 (2001)	
	60	MELLOR, A. L. et al., Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses, *J. Immunol.,* **168**, 3771-3776, 2002	
	61	MIKI, T. et al., Blockade of tryptophan catabolism prevents spontaneous tolerogenicity of liver allografts, *Transplantation Proceedings,* **33**, 129-130, 2001[	
	62	MULLER, A. et al, Involvement of chemokine receptors in breast cancer metastasis, *Nature*, **410:** 50-56, 2001	
	63	MUNN, D. H. et al., Prevention of allogeneic fetal rejection by tryptophan catabolism, *Science,* **281**, 1191-1193, 1998	
	64	MUNN, D. H. et al., Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxgenase, *Science,* **297**, 1867-1870, 2002	
	65	MUNN, D. H. et al., Inhibition of T cell proliferation by macrophage tryptophank catabolism, *J. Exp. Med.,* **189**, 1363-1372, 1999	
	66	NEUHAUS, D. et al, *The Nuclear Overhauser Effect in Structural and Conformational Analysis*, VCH New York, Chapter 8, The Two- Dimensional NOESY Experiment, 1989, pp. 253-305	
	67	OCHSENBEIN, A. F. et al., Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction, *Nature,* **411**, 1058-1064, 2001	
	68	OLWEUS, J. et al., Dendritic cell ontogeny: A human dendritic	

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		cell lineage of myeloid origin, *Proc. Natl. Acad. Sci. USA,* **94**, 12551-12556, 1997	
	69	PALCZEWSKI, K. et al., Crystal structure of rhodopsin: A G protein—coupled receptor, *Science* **289:** 739-745, 2000	
	70	PICKL, W. F. et al., Molecular and functional characteristics of dendritic cells generated from highly purified $CD14^+$ peripheral blood monocytes, *J. Immunol.,* **157**, 3850-3859, 1996	
	71	PIOTTO, M. et al, Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions, *J. Biomol. NMR.,* **2:** 661-665, 1992	
	72	REDDY, A. et al., A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells, *Blood,* **90**, 3640-3646, 1997	
	73	RIDGE, J. P. et al., A conditioned dendritic cell can be a temporal bridge between a $CD4^+$ T-helper and a T-killer cell, *Nature,* **393**, 474-478, 1998	
	74	SAKAGUCHI, S., Regulatory T cells: key controllers of immunologic self-tolerance, *Cell,* **101**, 455-458, 2000	
	75	SALI, A. et al., Definition of general topological equivalence in protein structures, *J. Mol. Biol.,* **212,** 403-428, 1990	
	76	SCHOENBERGER, S. P. et al., T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions, *Nature,* **393**, 480-483, 1998	
	77	SHEVACH, E. M., Certified professionals: CD4+CD25+ suppressor T cells, *J. Exp. Med.,* **193**, F41-F45, 2001	
	78	SHORTMAN, K. et al., Immunity or tolerance? That is the question for dendritic cells, *Nature Immunol.,* **2**, 988-989, 2001	
	79	SHORTMAN, K. et al., Mouse and human dendritic cell subtypes, *Nature Reviews: Immunology,* **2**, 151-161, 2002	
	80	SMYTH, M. J., et al., A fresh look at tumor immunosurveillance and immunotherapy, *Nature,* **2**, 293-298, 2001	
	81	SOTOMAYER, E. J. et al., Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-call lymphoma progression, *Blood,* **98**, 1070-1077, 2001	
	82	SOZZANI, S. et al., The role of chemokines in the regulation of dendritic cell trafficking, *J. Leukocyte Biol.,* **66**, 1-9, 1999	
	83	SPATOLA, A.F. et al, Rediscovering an endothelin antagonist	

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		(BQ-123): a self-deconvoluting cyclic pentapeptide library, *J. Med. Chem.*, **39**: 3842-3846, 1996	
	84	SPATOLA, A.F., Chemistry and Biochemistry of Amino Acids, Peptides, and Proteins, ed. B. Weinstein et al, New York, Vol. VII, pp. 267-357, 1983	
	85	STAVELEY-O'CARROLL, K. et al., Induction of antigen-specific T cell anergy: An early event in the course of tumor progression, *Proc. Natl. Acad. Sci. USA*, **95**, 1178-1183, 1998	
	86	SUMMERS, K. L. et al., Phenotypic characterization of five dendritic cell subsets in human tonsils, *Am. J. Pathol.*, **159**, 285-295, 2001	
	87	SUTMULLER, R. P. M. et al., Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of $CD25^+$ regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses, *J. Exp. Med.*, **194**, 823-832, 2001	
	88	SZABOLCS, P. et al., Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate, *Blood*, **87**, 4520-4530, 1996	
	89	TARAZONA, R. et al, Effects of different antigenic microenvironments on the course of CD8+ T cell responses in vivo, *Int. Immunol.*, **8,** 351-358, 1996	
	90	TAYLOR, M. W. et al., Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism, *FASEB J.*, **5**, 2516-2522, 1991	
	91	THOMPSON, A. W. et al., Are dendritic cells the key to liver transplant tolerance?, *Immunol. Today*, **20**, 27-31, 1999	
	92	TODRYK, S., A sense of tumour for the immune system, *Immunol.*, ***107, 1-4, 2002***	
	93.	van ELSAS, A. et al., Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation, *J. Exp. Med.*, **190**, 355-366, 1999	
	94	van ELSAS, A. et al., Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with	

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

		a B16 melanoma vaccine: comparison of prophylaxis and therapy, *J. Exp. Med.,* **194**, 481-489, 2001	
	95	VARONA, R. et al., CCR6-deficient mice have impaired leukocyte homeostasis and altered contact hypersensitivity and delayed-type hypersensitivity responses, *J. Clin. Invest.,* **107**, R37-R45, 2001	
	96	WALDMANN, H. et al., Regulating the immune response to transplants: a role for $CD4^+$ regulatory cells?, *Immunity,* **14**, 399-406, 2001	
	97	WISHART, D.S. et al., 1H, 13C and 15N chemical shift referencing in biomolecular NMR, *J. Biomol. NMR*, **6,** 135-140, 1995	
	98	YANG, D. et al., Cutting edge: Immature dendritic cells generated from monocytes in the presence of TGF-β1 express functional C-C chemokine receptor 6, *J. I*mmunol., ***163,*** *1737-1741, 1999*	
	99	ZLOTNIK, A. et al., Chemokines: a new classification system and their role in immunity, *Immunity,* **12**, 121-127, 2000	
	100	MORITA, Y. et al., Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis, *J. Clin. Invest.,* **107**, 1275-1284, 2001	
	101	MORSE, M.A. et al., Technology evaluation: Theratope, Biomira Inc., *Curr. Opin. Mol. Ther.,* Aug **2(4)**:453-458, 2000	
	102	MORSE, M. A. et al., Clinical applications of dendritic cell vaccines, *Current Opinion in Molecular Therapeutics*, **2(1)**:20-28, 2000	
	103	NAIR, S. K. et al., Induction of carcinoembroyonic antigen (CEA)-specific cytotoxic T-lymphocyte responses *in* vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastic malignancies expressing CEA, *Int. J. Cancer,* **82**, 121-124, 1999	
	104	POLUEKTOVA, L. Y. et al., Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis, *J Immunol.,***168**:3941-3949, *2002*	
	105	RONCAROLO, M. G. et al., Differentiation of T regulatory cells by immature dendritic cells, *J. Exp. Med.,* **193**, F5-F9, 2001	
	106	YOON, J.-W. et al., Control of autoimmune diabetes in NOD mice by GAD expression or suppression of β cells, *Science,* **284**, 1183-1187, 1999	

Please type a plus sign (+) inside this box → [+]

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449APTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known	
Application Number	10/660,131
Filing Date	September 11, 2003
First Named Inventor	David H. Munn
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	M0351-287806
Express Mail Certificate	EV 127 541 682 US

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.[1] Unique citation designation number. [2] Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

[3]